Dublin, Jan. 21, 2025 (GLOBE NEWSWIRE) -- The "Botanical and Plant-derived Drugs Market 2025-2029" report has been added to ResearchAndMarkets.com's offering.
The botanical and plant-derived drugs market is forecasted to grow by USD 18.66 billion during 2024-2029, accelerating at a CAGR of 7.4% during the forecast period. The market is driven by the rising government initiatives promoting the use of plant-derived drugs, limitations associated with conventional drugs, and the growing demand for effective treatment of chronic disorders.
The study identifies the transformation of the regulatory landscape in the U.S. as one of the prime reasons driving the botanical and plant-derived drugs market growth during the next few years. Also, the growing focus on the development of drugs for new medical fields and the emergence of new entrants with innovative products will lead to sizable demand in the market.
This report on the botanical and plant-derived drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors. The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment.
The botanical and plant-derived drugs market is segmented as below:
By Type
- Oral
- Injectables
- Topicals
By Application
- Infectious diseases
- Central nervous system
- Cardiovascular diseases
- Respiratory diseases
- Others
By Region
- Asia
- Europe
- North America
- Rest of World (RoW)
A robust vendor analysis within the report is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading botanical and plant-derived drugs market vendors.
Also, the botanical and plant-derived drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
A selection of companies mentioned in this report includes, but is not limited to:
- Bausch Health Companies Inc.
- Bayer AG
- Boehringer Ingelheim International GmbH
- Devonian Health Group Inc.
- Dr. Willmar Schwabe GmbH and Co. KG
- F. Hoffmann La Roche Ltd.
- Hetero Labs Ltd.
- Jaguar Health Inc.
- Jazz Pharmaceuticals Plc
- Medigene AG
- Merck KGaA
- Novartis AG
- Pfizer Inc.
- Pierre Fabre SA
- Protalix Biotherapeutics Inc.
- Riaan Wellness Pvt. Ltd.
- Sanofi SA
- Sun Pharmaceutical Industries Ltd.
- Vertex Pharmaceuticals Inc.
For more information about this report visit https://www.researchandmarkets.com/r/jiao40
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
